Latest Breaking News On - Venrock healthcare capital partners - Page 7 : comparemela.com

Edgewise expects to raise $240M with stock offering

Clinical-stage, pre-revenue pharmaceutical company Edgewise Therapeutics Inc. (Nasdaq: EWTX) plans to sell nearly 22 million new shares of common stock, an offering that it expects to raise about $240 million.

Frazier life sciencesNovo holdingsEdgewise therapeutics incEdgewise therapeuticsBecker muscular dystrophyDuchenne muscular dystrophyVenrock healthcare capital partnersCormorant asset managementJanus henderson investorsPerceptive advisorsSurveyor capital

Edgewise expects to raise $240M with stock offering – BizWest

Edgewise expects to raise $240M with stock offering – BizWest
bizwest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizwest.com Daily Mail and Mail on Sunday newspapers.

Frazier life sciencesNovo holdingsEdgewise therapeutics incEdgewise therapeuticsBecker muscular dystrophyDuchenne muscular dystrophyVenrock healthcare capital partnersCormorant asset managementJanus henderson investorsPerceptive advisorsSurveyor capital

Baystreet ca - ORIC Hails Private Placement

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) saw its shares shoot up Monday. The San Francisco-based clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that it has agreed to .

Frazier life sciencesOric pharmaceuticals incSan francisco basedViking global investorsCommodore capitalVenrock healthcare capital partners

ORIC Pharmaceuticals (ORIC) Prices 12 5M Share Offering at $10/sh

ORIC Pharmaceuticals (ORIC) Prices 12 5M Share Offering at $10/sh
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrazier life sciencesOric pharmaceuticals incExchange commissionViking global investorsCommodore capitalVenrock healthcare capital partnersSecurities act

Dianthus Therapeutics Announces $230 Million Private Placement

NEW YORK and WALTHAM, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) Dianthus Therapeutics, Inc. (“Dianthus” or the “Company”) (NASDAQ: DNTH), a clini.

New yorkUnited statesRaymond jamesTellus bioventuresExchange commissionDianthus therapeutics incBain capital life sciencesGreat point partnersCompany quarterly report on formAvidity partnersVenrock healthcare capital partnersOctagon capitalJanus henderson investorsVestal point capitalLogos capitalCatalio capital management